RT Journal Article
SR Electronic
T1 ARE POTENTIALLY RESECTABLE COLORECTAL LIVER METASTASES SLIPPING THROUGH THE NET?
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP A9
OP A9
DO 10.1136/gutjnl-2013-305143.20
VO 62
IS Suppl 2
A1 N Keville
A1 C Jones
A1 A McAfee
A1 J Ahmad
A1 B Dasari
A1 L McKie
A1 M A Taylor
A1 T Diamond
YR 2013
UL http://gut.bmj.com/content/62/Suppl_2/A9.2.abstract
AB Introduction Liver is the most common site of metastatic spread in colorectal cancer, and its management has significantly evolved in recent decades with liver resection now being the optimal treatment. Aims/Background This study aimed to assess referral patterns from colorectal multidisciplinary meetings (MDMs) throughout Northern Ireland to the Regional HPB Unit. Method Over a 6 week period all colorectal MDMs throughout the five health and social care trusts were reviewed. Patients with colorectal liver metastases (CRLMs) were included in the study. The following data were included: patient demographics, details of the health and social care trust, date of MDM discussion, primary tumour pathology, and the MDM outcome. These findings were subsequently compared with regional guidelines for the referral of CRLMs to assess if the decision was deemed appropriate. Results 21 discussions were recorded, which involved 20 patients, with a mean age of 69 years and 13 were male. 40% of patients were from the Belfast trust, while the remainder was evenly distributed between the 4 remaining trusts. All CRLMs discussed were confirmed by computerised tomography scanning, and the MDM decision was deemed to be appropriate in 85% of patients. Only 15% of patients had KRAS testing performed and 20% were subsequently referred for PET-CT scanning. Conclusion The majority of potentially resectable colorectal liver metastases had an appropriate outcome in terms of management and referral to the Regional HPB unit. However, this could still be further streamlined through both education, and highlighting the role of PET-CT and KRAS testing.